TGTX Q4 2025 Earnings Call Summary

TG Therapeutics Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Total Global Revenue: Approximately $616 million for 2025, with Q4 contributing $183 million.
BRIUMVI U.S. Net Sales: $594 million for the year, with Q4 net sales at $182.7 million.
Net Income: $447.2 million for the year ($2.77 per diluted share), significantly up from $23.4 million ($0.15 per diluted share) in 2024. This includes a nonrecurring tax benefit of $340 million.
Operating Income: $123 million for 2025, driven by revenue growth exceeding operating expense increases of approximately $328 million.
Cash Position: Over $600 million in current assets, including $200 million in cash and equivalents.

2. Strategic Updates and Business Highlights

BRIUMVI Performance: Demonstrated strong growth with 92% year-over-year increase in Q4. The drug is gaining traction as a foundational therapy for relapsing multiple sclerosis (RMS).
Clinical Data: Positive long-term data from ULTIMATE I and II studies presented, showing high efficacy and safety profiles.
R&D Initiatives:
- ENHANCE Study: Phase III trial for a consolidated dosing schedule is complete, with top-line data expected mid-2026.
- Subcutaneous BRIUMVI: Phase III study is 75% enrolled, with pivotal data anticipated late 2026 or early 2027.
- Exploration of Additional Indications: Investigating BRIUMVI in other autoimmune diseases, including Myasthenia Gravis.
Partnerships and Community Engagement: Launched the Next In MS initiative with Christina Applegate to support MS patients and raise awareness.

3. Forward Guidance and Outlook

2026 Revenue Guidance: U.S. BRIUMVI net revenue projected between $825 million and $850 million, with total global revenue expected to reach $875 million to $900 million.
Q1 2026 Expectations: Anticipated U.S. revenue growth to approximately $185 million to $190 million, despite typical seasonal headwinds.

4. Bad News, Challenges, or Points of Concern

Gross to Net Variability: Fluctuations expected due to deductible resets and co-pay program utilization, particularly in Q1, which may impact revenue recognition.
Competitive Pressures: Notable competition from Roche and Novartis in the subcutaneous market, which could affect market share dynamics.
Expense Projections: Expected operating expenses for 2026 are projected at approximately $350 million, plus additional costs for subcutaneous BRIUMVI manufacturing.

5. Notable Q&A Insights

Market Dynamics: Strong growth in new patient starts, but some analysts expressed concerns about the pace of growth relative to guidance, suggesting potential conservatism in revenue estimates.
Subcutaneous Launch Strategy: Minimal incremental costs anticipated for the subcutaneous launch due to overlap with the existing sales force.
DTC Campaign Metrics: Early engagement metrics from the Next In MS initiative have exceeded expectations, indicating positive reception and potential for increased brand visibility.

Overall, TG Therapeutics reported a strong performance in 2025, with significant revenue growth driven by BRIUMVI. The company is strategically positioned for continued expansion in 2026, although it faces competitive pressures and variability in revenue recognition.

TGTX — TG Therapeutics, Inc.